Trial Profile
Effect of concomitant use of formula diet with dapagliflozin on body compositions, metabolic improvement, and its safety in type 2 diabetes mellitus.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jan 2020
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms Diet-Dapper study
- 20 Sep 2019 Primary endpoint (The variation of HbA1c from starting time of the therapy to 24 weeks after starting the therapy in between two groups Summary statistics of the change of HbA1c is calculated, and the variation from starting time of the therapy to 24 weeks after starting the therapy are compared between the two groups by the two sample t-test.) has not been met as per results presented at the 55th Annual Meeting of the European Association for the Study of Diabetes.
- 15 May 2019 Status changed from active, no longer recruiting to completed.
- 09 Jul 2018 Status changed from recruiting to active, no longer recruiting.